📊 LIMNW Key Takeaways
Is Liminatus Pharma, Inc. (LIMNW) a Good Investment?
Liminatus Pharma exhibits critical financial distress with negative stockholders equity of -9.8M, negative operating cash flow of -10.0M, and only 337.7K in cash against 10.3M in liabilities. At current burn rate, the company has approximately 2 weeks of cash runway, creating imminent bankruptcy risk regardless of pipeline potential.
Liminatus is a pre-revenue biotech with acute financial strain: net loss of ~$10.2M, negative equity (~$9.8M), and minimal cash (~$0.34M) against a 0.05x current ratio. With operating cash outflow near ~$10M and virtually no liquidity, continued operations appear dependent on near-term external financing or restructuring. Until there is clear revenue traction or material strengthening of the balance sheet, fundamentals remain very weak.
Liminatus Pharma, Inc. Key Strengths (LIMNW)
- Pre-revenue biotech stage is typical for drug development companies
- Cash position of 337.7K provides minimal near-term operating flexibility
- Sector (biological products) represents growth market if company survives
- Low capital intensity (capex ~ $13K).
- No reported long-term debt obligations.
- Potential operating leverage if commercialization begins.
LIMNW Stock Risks: Liminatus Pharma, Inc. Investment Risks
- Negative stockholders equity of -9.8M indicates technical insolvency
- Critically low current ratio of 0.05x - severe liquidity crisis with only $0.05 in current assets per $1 of current liabilities
- Unsustainable cash burn of -10.0M annually with only 2 weeks of cash remaining at current burn rate
- No revenue generation and -10.2M net loss with deteriorating EPS
- Liabilities (10.3M) exceed assets (512.8K) by 20x, indicating inability to meet obligations
- Severe liquidity shortfall (current ratio 0.05x; cash ~$0.34M).
- Negative stockholders’ equity and high liabilities imply solvency/dilution risk.
- No revenue with large cash burn (OCF ~$-9.96M) raises going-concern risk.
Key Metrics to Watch
- Cash position and runway - critical monitoring given 2-week burn timeline
- Debt restructuring or bankruptcy proceedings announcements
- Dilutive financing activity or capital raise announcements
- Operating cash flow and free cash flow burn.
- Cash and equivalents and current ratio.
Liminatus Pharma, Inc. (LIMNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
LIMNW Profit Margin, ROE & Profitability Analysis
LIMNW vs Healthcare Sector: How Liminatus Pharma, Inc. Compares
How Liminatus Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Liminatus Pharma, Inc. Stock Overvalued? LIMNW Valuation Analysis 2026
Based on fundamental analysis, Liminatus Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Liminatus Pharma, Inc. Balance Sheet: LIMNW Debt, Cash & Liquidity
LIMNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Liminatus Pharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.20 indicates the company is currently unprofitable.
LIMNW Revenue Growth, EPS Growth & YoY Performance
Liminatus Pharma, Inc. Dividends, Buybacks & Capital Allocation
LIMNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Liminatus Pharma, Inc. (CIK: 0001971387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIMNW
What is the AI rating for LIMNW?
Liminatus Pharma, Inc. (LIMNW) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIMNW's key strengths?
Claude: Pre-revenue biotech stage is typical for drug development companies. Cash position of 337.7K provides minimal near-term operating flexibility. ChatGPT: Low capital intensity (capex ~ $13K).. No reported long-term debt obligations..
What are the risks of investing in LIMNW?
Claude: Negative stockholders equity of -9.8M indicates technical insolvency. Critically low current ratio of 0.05x - severe liquidity crisis with only $0.05 in current assets per $1 of current liabilities. ChatGPT: Severe liquidity shortfall (current ratio 0.05x; cash ~$0.34M).. Negative stockholders’ equity and high liabilities imply solvency/dilution risk..
What is LIMNW's revenue and growth?
Liminatus Pharma, Inc. reported revenue of N/A.
Does LIMNW pay dividends?
Liminatus Pharma, Inc. does not currently pay dividends.
Where can I find LIMNW SEC filings?
Official SEC filings for Liminatus Pharma, Inc. (CIK: 0001971387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIMNW's EPS?
Liminatus Pharma, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LIMNW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Liminatus Pharma, Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LIMNW stock overvalued or undervalued?
Valuation metrics for LIMNW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LIMNW's AI grade for 2026?
Our dual AI analysis gives Liminatus Pharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIMNW's free cash flow?
Liminatus Pharma, Inc.'s operating cash flow is $-10.0M, with capital expenditures of $13.1K.
How does LIMNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.05 (avg: 2).